Success and failure of vaccines against renin–angiotensin system components

@article{Brown2009SuccessAF,
  title={Success and failure of vaccines against renin–angiotensin system components},
  author={Morris J. Brown},
  journal={Nature Reviews Cardiology},
  year={2009},
  volume={6},
  pages={639-647}
}
Therapeutic vaccination pre-dated modern drugs as a possible strategy for treating hypertension. This approach is now being rediscovered, through use of modified angiotensins as immunogens together with carriers and adjuvants. Effective blockade of the renin–angiotensin system (RAS) with treatment twice a year might suit patients who dislike taking drugs on a daily basis and would also be an attractive option for those who have blood pressures in the prehypertensive range, if it can prevent… Expand
Vaccines against components of the renin–angiotensin system
TLDR
The different vaccination attempts with proteins and peptides against the different molecules of the renin–angiotensin system in the last two decades are reviewed, safety issues, and other novel prospects biomarkers in hypertension are summarized, and the potential of this immunomodulatory approach in clinical practice is summarized. Expand
Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals
TLDR
The ATRQ&bgr;-001 vaccine may provide a novel and promising method for the treatment of primary hypertension through diminishing the pressure response and inhibiting signal transduction initiated by Ang II. Expand
Therapeutic Vaccines against Human and Rat Renin in Spontaneously Hypertensive Rats
TLDR
The antigenic peptide hR32 vaccine mimicking the 32Asp catalytic site of human renin may constitute a novel tool for the development of a renin vaccine. Expand
Emerging drugs which target the renin–angiotensin–aldosterone system
TLDR
The search for drugs activating these tissue-protective arms of RAAS is the most innovative field in RAAS pharmacology, as newly discovered targets have functions beyond the cardiovascular system opening up novel therapeutic areas for drugs interfering with RAAS components. Expand
Clinical study on angiotensin II vaccination—the first big step
  • M. Mogi
  • Medicine
  • Hypertension Research
  • 2021
TLDR
The present study was a phase I/IIa study of the angiotensin II vaccine AGMG0201 in patients with mild-to-moderate essential hypertension, and the vaccine was well tolerated at both low and high doses. Expand
New Molecules for Treating Resistant Hypertension: a Clinical Perspective
TLDR
Clinical trials of new molecules targeting both well-established and more recently elucidated pathophysiologic mechanisms of hypertension offer a multitude of potential treatment avenues that warrant further evaluation in the context of RH. Expand
An Interesting Vaccine
TLDR
The crucial role of renin angiotensin aldosterone system (RAAS) in the pathogenesis of hypertension is now well recognized and the use of drugs to block this system has become an important modality in the management of hypertension. Expand
New approaches in the treatment of hypertension.
TLDR
New drugs and interventional treatments that are undergoing preclinical or clinical testing for hypertension treatment are discussed, but none of these novel drug or device treatments has been shown to prevent cardiovascular disease outcomes or death in hypertensive patients. Expand
Gene therapy for hypertension
TLDR
Increased gene transfection efficacy necessary for a systemic treatment, personalized identification of the implied aetiology from the multifactorial background and evidence from larger mammals are required for gene therapy to compete with the broad spectrum of current therapeutic options in hypertension. Expand
Renin inhibition by soyasaponin I: a potent native anti-hypertensive compound
TLDR
The results of this survey might be helpful to design partial non – competitive renin inhibitors with pharmaceutical capability and have partial non-competitive effect. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 88 REFERENCES
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity
TLDR
AngQb reduces blood pressure in SHR to levels obtained with an ACE inhibitor, and is immunogenic and well tolerated in humans, Therefore, vaccination against angiotensin II has the potential to become a useful antihypertensive treatment providing long-lasting effects and improving patient compliance. Expand
Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.
TLDR
KH was shown to be a suitable alternative to TT as a carrier protein for AI, thus supporting continued evaluation of the AI-KLH conjugate vaccine for treatment of hypertension in man. Expand
Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.
TLDR
Biochemical measurements show evidence of blockade of the renin system, but higher titres will be required to achieve a decrease in blood pressure, as shown in patients with essential hypertension. Expand
Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'.
TLDR
Preliminary results of Ang I (angiotensin I) immunization in humans demonstrate the presence of antibodies in human plasma and report that the procedure is well tolerated, but the blood pressure does not fall. Expand
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study
TLDR
Immunisation with CYT006-AngQb-a vaccine based on a virus-like particle-that targets angiotensin II to reduce ambulatory blood pressure was associated with no serious adverse events; most observed adverse events were consistent with local or systemic responses similar to those seen with other vaccines. Expand
Immunologic approaches to blockade of the renin-angiotensin system: a review.
TLDR
In all cases immunologic methods offer in vivo experimental models of short- or long-term RAS blockade that could be compared with pharmacologic methods, such as converting-enzyme inhibition, angiotensin II antagonists, and renin inhibitors. Expand
Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats
TLDR
Findings indicate that active immunization against AI may be a useful approach for treating cardiovascular disorders involving the renin‐angiotensin system. Expand
Active and Passive Immunization Against Angiotensin II in the Rat and Rabbit: EVIDENCE FOR A NORMAL REGULATION OF THE RENIN-ANGIOTENSIN SYSTEM
TLDR
It is concluded that the renin-angiotensin system in antibody-injected rats was regulated at a normal level, and feedback mechanisms which control renin secretion, such as free plasma angiotens in II concentrations, are in the normal range. Expand
Better blood pressure control: how to combine drugs
TLDR
This article shows how the consistency of both theory and a broad range of evidence permits a didactic approach to combination therapy and advises against combining ‘B’ and ‘D’ in older patients, and to recommend ‘A’ + ‘C” + “D” as standard triple therapy for resistant hypertension. Expand
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
TLDR
It is demonstrated that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects. Expand
...
1
2
3
4
5
...